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1. Data {#sec1}
=======

The sample of the PsyTAR contains 891 drug reviews collected randomly from an online healthcare forum "askapatient.com". [Fig. 1](#fig1){ref-type="fig"} shows the share of the sample for four drugs "Zoloft" and "Lexapro" from SSRIs (Selective Serotonin Reuptake Inhibitors) class and "Effexor XR" and "Cymbalta" from the SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) class. [Fig. 2](#fig2){ref-type="fig"} shows the gender demographic distribution of the sample. The average of age and duration of usage were 37 and 18 months for the whole sample respectively.Fig. 1Sample sizes for the four drugs of the dataset.Fig. 1Fig. 2Gender distribution in the sample.Fig. 2

In the second phase, drug review posts were split into sentences, and then sentences were labeled for the presence of ADRs (Adverse drug reaction), WDs (Withdrawal Symptoms), SSIs (sign, symptom, illness), DIs (Drug Indications), EF (drug effectiveness), and INF (drug ineffectiveness). The total number of sentences in the sample is 6009. [Fig. 3](#fig3){ref-type="fig"} shows frequency of sentences labeled for each of these items for the whole PsyTAR dataset and SSRI and SNRI classes separately.Fig. 3Frequency of sentences labeled for each item in the dataset, and SSRIs and SNRIs class separately.Fig. 3

In the third phase, mentions of ADRs, WDs, SSIs, and DIs were identified and extracted from the sentences, and then classified as physiological, psychological, cognitive, or functional problem. [Fig. 4](#fig4){ref-type="fig"} shows the total frequency of identified ADRs, WDs, DIs, and SSIs broken down by the type of entity including physiological, psychological, cognitive, and functional problems. [Fig. 5](#fig5){ref-type="fig"} shows the percentage of identified ADRs, WDs, DIs, and SSIs for the entire PsyTAR dataset and type of entities separately.Fig. 4Frequency of cognitive, physiological, psychological, and functional problems entity type by ADRs, WDs, DIs, and SSIs for the entire dataset.Fig. 4Fig. 5Percentage of cognitive, physiological, psychological, and functional problems entity types by ADRs, WDs, DIs, and SSIs in the entire dataset.Fig. 5

In the fourth phase, all the identified entities were mapped to 918 unique UMLS concepts and 755 unique SNOMED CT concepts. [Fig. 6](#fig6){ref-type="fig"} shows frequency of UMLS concepts for each ADRs, WDs, DIs, and SSIs. The 3180 unique identified ADRs in the third phase were mapped to 673 UMLS concepts, indicating the high semantic variabilities of patients expression of ADRs [@bib1]. [Fig. 7](#fig7){ref-type="fig"} shows the reduction of identified entities by mapping to the UMLS Metathesaurus concepts.Fig. 6Frequency of UMLS concepts for each ADRs, WDs, DIs, SSIs after normalization.Fig. 6Fig. 7Reduction of identified entities by mapping to the UMLS Metathesaurus concepts.Fig. 7

In this phase, we also identified qualifiers indicating severity and persistency of identified entities. [Fig. 8](#fig8){ref-type="fig"} shows the frequency of identified qualifiers including "mild", "moderate", and "severe" indicating severity, and "persistent" and "not-persistent" indicating persistency of the identified entities (ADRs, WDs, DIs, SSIs).Fig. 8Frequency of identified entities indicating severity and persistency of the identified entities (ADR, WD, DI, SSI).Fig. 8

2. Experimental design, materials and methods {#sec2}
=============================================

The drug reviews were collected from a healthcare forum called "askapatient.com". We developed an Application Programming Interface (API) to collect data from this forum. The sample size was calculated using the formula of sample size for qualitative studies [@bib2]. In the next step, the drug reviews were processed for correcting grammatical errors and removing personal information (e.g., website, emails). Then, the reviews were split into sentences, and each sentence was double coded (labeled) for the presence of ADR, WD, DI, SSI, EF, and INF. The calculated inter-annotator agreement (IAA) using Kappa was 78% for the entire dataset. In the next phase, mentions of the ADR, WD, SSIs, and DIs were identified from the relevant sentences. Four annotators identified the boundary of the entities by strictly following guidelines developed for the entity identification phase. The calculated IAA for entity identification was 86% for the entire dataset. In the last phase, the identified entities were mapped to the corresponding UMLS Metathesaurus concepts and SNOMED CT concepts. All of the identified concepts were reviewed for consistency. The detailed methodology for developing this dataset is discussed in a separate manuscript [@bib1].
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